kabutan

GNI Group Ltd.(2160) Summary

2160
TSE Growth
GNI Group Ltd.
2,519
JPY
+12
(+0.48%)
Jan 29, 3:06 pm JST
16.45
USD
Jan 29, 1:06 am EST
Result
PTS
outside of trading hours
2,525.9
Jan 29, 3:04 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.80
Yield
ー%
Margin Trading Ratio
41.51
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
2,508 JPY 16.38 USD
Previous Close Jan 28
2,507 JPY 16.42 USD
High Jan 29, 11:07 am
2,539 JPY 16.58 USD
Low Jan 29, 9:01 am
2,465 JPY 16.09 USD
Volume
657,900
Trading Value
1.65B JPY 0.01B USD
VWAP
2509.36 JPY 16.39 USD
Minimum Trading Value
251,900 JPY 1,645 USD
Market Cap
0.14T JPY 0.92B USD
Number of Trades
2,336
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
4,123
1-Year High May 27, 2025
36,454
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 675,000 5,988,200 8.87
Jan 16, 2026 960,700 6,016,300 6.26
Jan 9, 2026 889,400 6,189,700 6.96
Dec 26, 2025 879,500 6,445,200 7.33
Dec 19, 2025 875,200 6,752,800 7.72
Company Profile
GNI Group Ltd. is a biotech venture company focused on drug discovery. It has research and development centers in the United States and China. The company's main product is a drug for idiopathic pulmonary fibrosis. They are also involved in genetic analysis.
Sector
Pharmaceuticals
GNI Group Ltd. operates in both the pharmaceutical and medical device sectors. In its pharmaceutical business, the company sells F351 (Etuary), a treatment for fibrosis, in the Chinese market. They also conduct research, development, manufacturing, and sales of drug compounds targeting lung diseases (interstitial lung diseases), liver diseases, and kidney diseases (chronic kidney disease). The medical device business is based in the United States and focuses on the development, manufacturing, and sales of biomaterials. The group consists of the parent company, 18 consolidated subsidiaries, and 2 affiliated companies. They also provide services such as reagents, designated manufacturing and marketing of medical devices, and domestic clinical trial management.